Dr. Annkathrin Hanssen

Alliance Manager for Nordic Astra Zeneca-DS Alliance. Planning and leading negotiations on FTE/ budget allocation (5 countries). Leading governance/ operating model definitions. Launch Lead for block buster DS8201. Leading launch readiness, brand strategy and sales set-up; leadership of marketing and sales functions and matrix leadership of cross-alliance, cross-functional brand team. Right hand to Nordic CEO: e.g. setting up supply chain, leading affiliate senior mgmt visits, team conferences, recruitment.

Starting external engagement from scratch for our new DS affiliate in all 4 Nordic countries; building up network of key stakeholders and setting the foundation for DS first clinical trial in the Nordics; taking over local market access responsibilities. Analyzing Nordic supply chain set-up for creation of distribution network for new affiliate. Co-organizing Daiichi Sankyo Nordic office opening event.

Building up strong and trustful partnerships with breast cancer key experts with clear focus on patient centricity. Closely working in cross-functional teams with medical and market access on local level. In-depth analysis of accounts, influencers and regional to national networks: evaluation of opportunities and threats per account and development/ execution of strategic and tactical customer engagement plans.

Responsible for driving sales in Hamburg and Schleswig-Holstein during launch of Cabometyx (cabozantinib in advanced renal cell carcinoma) in Germany. Building up a strong network with key customers: Scientifically discussing and promoting the new treatment option; working cross-functionally towards the customer; organizing round tables to discuss indication and best practice/ experience sharing; facilitating and participating in local educational events, regional congresses and international conferences.

Department of Tumor Biology Topic: Detection and characterization of circulating tumor cells (CTCs) in non-small cell lung cancer (NSCLC)

Institut für Tumorbiologie (Prof. Dr. Klaus Pantel) Schwerpunkt: Zirkulierende Tumorzellen beim nicht-kleinzelligen Bronchialkarzinom

Auslands-Semester in Port Elizabeth, Südafrika